Octreotide
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acromegaly
Conditions
Acromegaly
Trial Timeline
Sep 1, 1999 → May 1, 2010
NCT ID
NCT00521300About Octreotide
Octreotide is a approved stage product being developed by Novartis for Acromegaly. The current trial status is completed. This product is registered under clinical trial identifier NCT00521300. Target conditions include Acromegaly.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00332969 | Phase 2 | Completed |
| NCT00171613 | Approved | Completed |
| NCT00171886 | Approved | Completed |
| NCT00241020 | Phase 3 | Completed |
| NCT00521300 | Approved | Completed |
Competing Products
20 competing products in Acromegaly
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alesse | Novartis | Phase 2 | 52 |
| ONO-5788 + ONO-5788 Placebo + Octreotide | Ono Pharmaceutical | Phase 1 | 33 |
| ONO-5788 + [14C]-ONO-5788 | Ono Pharmaceutical | Phase 1 | 33 |
| Pasireotide LAR | Novartis | Phase 3 | 77 |
| Octreotide acetate 30 mg suspension | Novartis | Phase 3 | 77 |
| Pasireotide long acting release formulation | Novartis | Pre-clinical | 23 |
| Sandostatin LAR + pegvisomant + cabergoline | Novartis | Approved | 85 |
| Octreotide acetate and cabergoline/Octrotide and Somavert | Novartis | Approved | 85 |
| Sandostatin LAR | Novartis | Approved | 85 |
| Pasireotide + Octreotide | Novartis | Phase 3 | 77 |
| Sandostatin (Octreotide Acetate) | Novartis | Approved | 85 |
| Octreotide acetate | Novartis | Approved | 85 |
| octreotide FluidCrystal® injection depot | Novartis | Phase 2 | 52 |
| Octreotide LAR | Novartis | Phase 3 | 77 |
| Octreotide LAR | Novartis | Phase 3 | 77 |
| Pasireotide | Novartis | Phase 2 | 52 |
| Pasireotide LAR 60 mg + Pegvisomant | Novartis | Approved | 85 |
| Octreotide LAR 30 MG Injection | Novartis | Approved | 85 |
| Pasireotide LAR | Novartis | Phase 2 | 52 |
| Pasireotide (SOM230), Octreotide (Sandostatin) | Novartis | Phase 2 | 52 |